Group 1 - TATA Health (1255.HK) resumed trading after more than 1.5 years and saw a significant increase, with midday gains reaching 723.33%, trading at HKD 2.47 [1] - The company is primarily engaged in shoe retail in Hong Kong and has met all resumption guidelines, including publishing outstanding financial results and demonstrating business viability [1] - The trading volume exceeded HKD 17 million, indicating strong market interest following the resumption [1]

Core Viewpoint - TATA Health (01255) has resumed trading after more than 1.5 years, experiencing a significant price surge of over 500%, reaching HKD 1.86 with a trading volume of HKD 6.33 million [1] Summary by Relevant Sections - **Resumption of Trading** - TATA Health has successfully met all resumption guidelines, allowing it to resume trading after a prolonged suspension [1] - **Financial Performance and Compliance** - The company has published all outstanding financial results and addressed any audit revisions [1] - TATA Health confirmed that its business operations are sustainable and that it possesses sufficient operational capacity and valuable assets to support its business activities [1] - **Internal Controls** - An independent internal control review has been conducted, demonstrating that the company has established adequate internal controls and procedures to fulfill its responsibilities under listing rules [1]

Core Viewpoint - TATA Health (01255) has resumed trading after more than 1.5 years, experiencing a significant surge of over 500% in early trading, reaching HKD 1.86 with a trading volume of HKD 6.33 million [1] Group 1 - The company announced that it has met all the resumption guidelines, which include publishing all outstanding financial results and addressing any audit revisions [1] - The group confirmed that its business is sustainable, with sufficient operational capacity and valuable assets to support its operations [1] - An independent internal control review has been conducted, demonstrating that the company has established adequate internal controls and procedures to fulfill its responsibilities under the listing rules [1]

Core Viewpoint - TATA Health (01255) has resumed trading after more than 1.5 years, experiencing a significant price surge of over 500% in early trading, reaching HKD 1.86 with a trading volume of HKD 6.33 million [1] Summary by Relevant Sections - **Resumption of Trading** - TATA Health has successfully met all resumption guidelines, allowing it to resume trading after a prolonged suspension [1] - **Financial Performance and Compliance** - The company has published all outstanding financial results and addressed any audit revisions, ensuring compliance with regulatory requirements [1] - **Business Viability** - TATA Health confirmed that its business operations are sustainable, with sufficient operational capacity and valuable assets to support ongoing business activities [1] - **Internal Controls** - An independent internal control review has been conducted, demonstrating that the company has established adequate internal controls and procedures to fulfill its responsibilities under listing rules [1]

Group 1 - TATA Health (01255.HK) announced that its shares will resume trading at 9:00 AM on December 1, 2025 [1]

Core Viewpoint - TATA Health (01255) has met all resumption guidelines and has applied to the Stock Exchange for the resumption of trading of its shares starting from December 1, 2025, at 9:00 AM [1] Summary by Relevant Sections - Company Status - TATA Health has achieved compliance with all necessary resumption guidelines [1] - The company has submitted an application to the Stock Exchange for the resumption of trading [1] - Trading Resumption - Shares of TATA Health are set to resume trading on December 1, 2025, at 9:00 AM [1]

Core Viewpoint - TATA Health has successfully met all resumption guidelines and will resume trading on the Hong Kong Stock Exchange on December 1, 2025 [1] Group 1 - The company has announced to its shareholders and potential investors that it has fulfilled all requirements for resumption [1] - Trading of the company's shares has been suspended since April 0, 2024, at 9:00 AM [1] - The application for resumption of trading has been submitted to the Stock Exchange [1]

應本公司要求，股份已於二零二四年四月二日上午九時正起暫停買賣。由於所有 復牌指引均已達成，本公司已向聯交所申請股份自二零二五年十二月一日上午九 時正起於聯交所恢復買賣。 本公告乃由TATA健康國際控股有限公司（「本公司」，連同其附屬公司，統稱「本集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09 條及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義見上市 規則）而作出。 達成所有復牌指引 董事會欣然知會其股東及潛在投資者，於本公告日期，本公司已達成所有復牌指 引。 恢復買賣 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） (1)達成所有復牌指引；及 (2)恢復買賣 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 達成所有復牌指引 董事會欣然宣佈，截 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） 內部控制審查的主要發現 及 繼續暫停買賣 本公告乃TATA健康國際控股有限公司（「本公司」，連同其附屬公司，統稱「本集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 13.09(2)(a)條及香港法例第571章證券及期貨條例（「證券及期貨條例」）第XIVA部項 下的內幕消息條文（定義見上市規則）而作出。 茲提述(i)本公司於二零二五年九月十日刊發的截至二零二三年十二月三十一日止年 度的全年業績（「二零二三年全年業績」）公告；及(ii)本公司日期為二零二五年九月 十五日的公告，內容有關聯交所對本公司施加的額外復牌指引（「額外復牌指引公 告」）。除另有界定者外，本公告所用詞彙與二零二三 ...

截至月份: 2025年10月31日 狀態: 新提交 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: TATA健康國際控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | 本月底法定 ...